NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price, Forecast & News

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals announced that its Board of Directors has approved a stock repurchase program on Tuesday, November 5th 2019, which allows the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 2.9% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's board of directors believes its stock is undervalued.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) released its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported $6.67 EPS for the quarter, topping analysts' consensus estimates of $5.13 by $1.54. The biopharmaceutical company had revenue of $2.05 billion for the quarter, compared to analysts' expectations of $1.98 billion. Regeneron Pharmaceuticals had a return on equity of 24.85% and a net margin of 28.13%. The business's revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the previous year, the firm posted $5.87 earnings per share. View Regeneron Pharmaceuticals' Earnings History.

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, February 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

20 equities research analysts have issued twelve-month price targets for Regeneron Pharmaceuticals' shares. Their forecasts range from $320.00 to $453.00. On average, they anticipate Regeneron Pharmaceuticals' share price to reach $391.78 in the next year. This suggests a possible upside of 13.8% from the stock's current price. View Analyst Price Targets for Regeneron Pharmaceuticals.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 11 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Regeneron Pharmaceuticals.

News headlines about REGN stock have trended somewhat negative on Friday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Regeneron Pharmaceuticals earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Regeneron Pharmaceuticals.

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include Netflix (NFLX), Gilead Sciences (GILD), Celgene (CELG), Biogen (biib), Alibaba Group (BABA), NVIDIA (NVDA), Tesla (TSLA), Amgen (AMGN), Alphabet (GOOG) and Broadcom (AVGO).

Regeneron Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.37%), Hexavest Inc. (0.08%), DNB Asset Management AS (0.06%), Wealthstreet Investment Advisors LLC (0.04%), Strs Ohio (0.04%) and Assenagon Asset Management S.A. (0.03%). Company insiders that own Regeneron Pharmaceuticals stock include Christopher R Fenimore, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

REGN stock was sold by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI, Rhenman & Partners Asset Management AB, OLD National Bancorp IN, Assenagon Asset Management S.A., Meag Munich Ergo Kapitalanlagegesellschaft MBH, Strs Ohio, Hexavest Inc. and State of Alaska Department of Revenue. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Christopher R Fenimore, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos and Sanofi. View Insider Buying and Selling for Regeneron Pharmaceuticals.

REGN stock was purchased by a variety of institutional investors in the last quarter, including First National Bank of Omaha, DNB Asset Management AS, Cardinal Capital Management, Nisa Investment Advisors LLC, Janney Montgomery Scott LLC, Exane Derivatives, Advisors Preferred LLC and Alpine Global Management LLC. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $344.20.

Regeneron Pharmaceuticals has a market capitalization of $37.79 billion and generates $6.71 billion in revenue each year. The biopharmaceutical company earns $2.44 billion in net income (profit) each year or $19.80 on an earnings per share basis. Regeneron Pharmaceuticals employs 7,400 workers across the globe.View Additional Information About Regeneron Pharmaceuticals.

The official website for Regeneron Pharmaceuticals is http://www.regeneron.com/.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]